Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

СПИСОК ЛИТЕРАТУРЫ

  1. National Institutes of Health NH, Lung, and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 2012.
  2. Reis S.E., Holubkov R., Conrad Smith A.J., Kelsey S.F., Sharaf B.L., Reichek N., et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001. 141(5): 735-741.
  3. Han S.H., Bae J.H., Holmes D.R., Jr., Lennon R.J., Eeckhout E., Barsness G.W., et al. Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J. 2008. 29(11): 1359-1369.
  4. Kitta Y., Obata J.E., Nakamura T., Hirano M., Kodama Y., Fujioka D., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009. 53(4): 323-330.
  5. Gulati M., Cooper-DeHoff R.M., McClure C., Johnson B.D., Shaw L.J., Handberg E.M., et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009. 169(9): 843-850.
  6. Jespersen L., Hvelplund A., Abildstrom S.Z., Pedersen F., Galatius S., Madsen J.K., et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012. 33(6): 734-744.
  7. Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007. 356(15): 1503-1516.
  8. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013. 34(38): 2949-3003.
  9. Bayturan O., Kapadia S., Nicholls S.J., Tuzcu E.M., Shao M., Uno K., et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010. 55(24): 2736-2742.
  10. Nicholls S.J., Hsu A., Wolski K., Hu B., Bayturan O., Lavoie A., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010. 55(21): 2399-2407.
  11. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012. 33(13): 1635-1701.
  12. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976. 295(7): 369-377.
  13. Мясников А.Л. Гипертоническая болезнь и атеросклероз. М.: Медицина, 1965.
  14. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009. 29(4): 431-438.
  15. Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J. Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011. 5(3): S9-S17.
  16. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013. 34(45): 3478-3490.
  17. Marks D., Thorogood M., Neil H.A.W., Humphries S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003. 168(1): 1-14.
  18. Genest J., Hegele R.A., Bergeron J., Brophy J., Carpentier A., Couture P., et al. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. Can J Cardiol. 2014. 30(12): 1471-1481.
  19. Law M., Rudnicka A.R. Statin Safety: A Systematic Review. Am J Cardiol. 2006. 97(8): S52-S60.
  20. Thompson P.D. Statin-Associated Myopathy. JAMA. 2003. 289(13): 1681.
  21. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006. 47(8 Suppl): C7-12.
  22. Руководство по кардиологии. В 4 т. / под ред. Е.И. Чазова. Т. 3. Кухарчук В.В.,Титов В.Н. Атеросклероз и дислипидемии. М.: Практика, 2014. С. 15-58.
  23. Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014. 114(12): 1852-1866.
  24. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VIII пересмотр. Атеросклероз и дислипидемии. 2020. №1.
  25. Климов А.Н., Никульчева Н.Г. Обмен липидов и липопротеидов и его нарушения: рукво для врачей. 3-е изд. СПб, 1999.
  26. Boytcov S.A., Urazalina S.J., Kukharchuk V.V., Balakhonova T.V., Sergienko I.V. Subclinical arterial wall damage in patients at low to moderate cardiovascular risk. Acta Cardiol. 2015. 70(3): 274-281.
  27. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020. 41(1): 111-188.
  28. Карпов Ю.А., Кухарчук В.В., Лякишев А.А., Лупанов В.П., Панченко Е.П., Комаров А.Л., и др. Диагностика и лечение хронической ишемической болезни сердца: клин. рек. М., 2013.
  29. Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: современные аспекты патогенеза, диагностики и лечения. М., 2017.
  30. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клинические рекомендации РКО, НОНР РАЭ, РМОАГ, НОА, РНМОТ. Российский кардиологический журнал. 2014. 8(112): 7-37.
  31. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013. 34(28): 2159-2219.
  32. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016. 37(29): 2315-2381.
  33. Бойцов С.А., Кухарчук В.В., Карпов Ю.А., Сергиенко И.В., Драпкина О.М., Семенова А.Е., и др. Субклинический атеросклероз как фактор риска сердечно-сосудистых осложнений. Кардиоваскулярная терапия и профилактика. 2012. 3: 82-86.
  34. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/ EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011. 217(1): 3-46.
  35. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016. 37(39): 2999-3058.
  36. Сергиенко И.В., Шестакова М.В., Бойцов С.А., Кухарчук В.В., Затейщиков Д.А., Ежов М.В., и др. Экстремальная категория риска в системе стратификации сердечно-сосудистых осложнений. Консенсус совета экспертов. Атеросклероз и дислипидемии. 2018. № 4 (31).
  37. Brott T.G., Halperin J.L., Abbara S., Bacharach J.M., Barr J.D., Bush R.L., et al. 2011 ASA/ ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. J Am Coll Cardiol. 2011. 57(8): 1002-1044.
  38. Sanz J., Fayad Z.A. Imaging of atherosclerotic cardiovascular disease. Nature. 2008. 451(7181): 953-957.
  39. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014. 35(37): 2541-2619.
  40. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019. 40(2): 87-165.
  41. Беленков Ю.Н., Сергиенко И.В., Лякишев А.А., Кухарчук В.В. Статины в современной кардиологической практике: моногр. М., 2007.
  42. Семенова А.Е., Сергиенко И.В. Фармакологические аспекты терапии статинами. Атеросклероз и дислипидемии. 2013. 2: 4-18.
  43. Семенова А.Е., Сергиенко И.В., Кухарчук В.В. Возможные механизмы стабилизации атеросклеротической бляшки на фоне терапии розувастатином. Атеросклероз и дислипидемии. 2010. 1: 20-24.
  44. Сергиенко И.В. Ингибирование всасывания холестерина в энтероцитах. Атеросклероз и дислипидемии. 2012. (1): 37-47.
  45. Руководство по кардиологии. В 4 т. / под ред. Е.И. Чазова. Т. 4. Кухарчук В.В., Сергиенко И.В. Гиполипидемические средства. М.: Практика, 2014. С. 864-874.
  46. Robinson J.G., Farnier M., Krempf M., Bergeron J., Luc G., Averna M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015. 372(16): 1489-1499.
  47. Sabatine M.S., Giugliano R.P., Wiviott S.D., Raal F.J., Blom D.J., Robinson J., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015. 372(16): 1500-1509.
  48. Кухарчук В.В., Бажан С.С. Пропротеин конвертаза субтилизин/кексин типа 9 (PCSK9) – регулятор экспрессии рецепторов липопротеинов низкой плотности. Атеросклероз и дислипидемии. 2013. (2): 19-27.
  49. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017. 376(18): 1713-1722.
  50. Reddy J.K., Azarnoff D.L., Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature. 1980. 283(5745): 397-398.
  51. Balendiran G.K., Rath N., Kotheimer A., Miller C., Zeller M., Rath N.P. Biomolecular chemistry of isopropyl fibrates. J Pharm Sci. 2012. 101(4): 1555-1569.
  52. Kockx M., Gervois P.P., Poulain P., Derudas B., Peters J.M., Gonzalez F.J., et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood. 1999. 93(9): 2991-2998.
  53. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., Галявич А.С., Гуревич В.С., Дупляков Д.В., и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012. 4: 70-78.
  54. Ridker P.M., Mora S., Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016. 37(17): 1373-1379.
  55. Vupputuri S., Joski P.J., Kilpatrick R., Woolley M.J., Robinson B.E., Farkouh M.E., et al. LDL cholesterol response and statin adherence among high-risk patients initiating treatment. Am J Manag Care. 2016. 22(3): e106-115.
  56. Kataoka Y., St John J., Wolski K., Uno K., Puri R., Tuzcu E.M., et al. Atheroma progression in hyporesponders to statin therapy. Arterioscler Thromb Vasc Biol. 2015. 35(4): 990-995.
  57. Feng Q., Wei W.Q., Chung C.P., Levinson R.T., Bastarache L., Denny J.C., et al. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J. 2016.
  58. Сергиенко И.В. Тактика лечения при неэффективности монотерапии статинами. Кардиоваскулярная терапия и профилактика. 2011. (4): 110-116.
  59. Barter P.J., Waters D.D. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol. 2018.
  60. Brignole M., Auricchio A., Baron-Esquivias G., Bordachar P., Boriani G., Breithardt O.A., et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013. 34(29): 2281-2329.
  61. Müller C. Xanthomata, Hypercholesterolemia, Angina Pectoris. Acta Med Scand. 1938. 95(S89): 75-84.
  62. Khachadurian A.K. The inheritance of essential familial hypercholesterolemia. Am J Med. 1964. 37(3): 402-407.
  63. Fredrickson D.S., Lees R.S. Editorial: A System for Phenotyping Hyperlipoproteinemia. Circulation. 1965. 31(3): 321-327.
  64. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013. 34(45): 3478-3490.
  65. Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Tonstad S., Wiegman A., et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews: Wiley-Blackwell; 2014.
  66. Сафарова М.С., Сергиенко И.В., Ежов М.В., Семенова А.Е., Качковский М.А., Шапошник И.И., и др. Российская научно-исследовательская программа по своевременной диагностике и лечению больных семейной гиперхолестеринемией: обоснование и дизайн российского регистра семейной гиперхолестеринемии (РоСГХС). Атеросклероз и дислипидемии. 2014. (3): 7-15.
  67. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004. 173(1): 55-68.
  68. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011. 5(3): 133-140.
  69. Ghosh S.K., Majumder B., Dutta A. Tuberous Xanthoma as a Presenting Feature of Familial Homozygous Hypercholesterolemia with Aortic Regurgitation. J Pediatr. 2015. 166(1): 198-198.e191.
  70. Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия. Современные аспекты диагностики, профилактики и терапии. Кардиология. 2009. (1): 76-83.
  71. Stein E.A. Statins and Children: Whom Do We Treat and When? Circulation. 2007. 116(6): 594-595.
  72. Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Strandberg T., Tonstad S., et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews: Wiley-Blackwell; 2010.
  73. McCrindle B.W., Urbina E.M., Dennison B.A., Jacobson M.S., Steinberger J., Rocchini A.P., et al. Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. Circulation. 2007. 115(14): 1948-1967.
  74. Rodenburg J., Vissers M.N., Wiegman A., van Trotsenburg A.S.P., van der Graaf A., de Groot E., et al. Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better. Circulation. 2007. 116(6): 664-668.
  75. Raal F.J., Honarpour N., Blom D.J., Hovingh G.K., Xu F., Scott R., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015. 385(9965): 341-350.
  76. Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci. 2009. 16(5): 431-437.
  77. Покровский С.Н., Кухарчук В.В., Афанасьева О.И., Кузнецова Ю.В., Коновалов Г.А., Адамова И.Ю., и др. Сорбционные технологии в лечении сердечно-сосудистых заболеваний. Кардиологический вестник. 2006. 1: 47-51.
  78. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019.
  79. Рекомендации по лечению стабильной ишемической болезни сердца. Российский кардиологический журнал. 2014. 111(7): 7-79.
  80. Ciszewski A., Bilinska Z.T., Brydak L.B., Kepka C., Kruk M., Romanowska M., et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008. 29(11): 1350-1358.
  81. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., Iwane M. Influenza Vaccination and Reduction in Hospitalizations for Cardiac Disease and Stroke among the Elderly. New England Journal of Medicine. 2003. 348(14): 1322-1332.
  82. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus Progestin and the Risk of Coronary Heart Disease. N Eng J Med. 2003. 349(6): 523-534.
  83. Cayla G., Silvain J., O’Connor S.A., Collet J.P., Montalescot G. Current antiplatelet options for NSTE-ACS patients. QJM. 2012. 105(10): 935-948.
  84. Collaboration A.T. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002. 324(7329): 71-86.
  85. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. EASD/ ESC. Российский кардиологический журнал. 2014. 107(3): 7-61.
  86. Henderson R.A., O’Flynn N., Guideline Development G. Management of stable angina: summary of NICE guidance. Heart. 2012. 98(6): 500-507.
  87. National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012. 60(5): 850-886.
  88. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can J Diabetes. 2016. 40(3): 193-195.
  89. Jones P.H., Hunninghake D.B., Ferdinand K.C., Stein E.A., Gold A., Caplan R.J., et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004. 26(9): 1388-1399.
  90. Stalenhoef A.F., Ballantyne C.M., Sarti C., Murin J., Tonstad S., Rose H., et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005. 26(24): 2664-2672.
  91. Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J.V., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005. 7(6): 1059-1069.
  92. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005. 352(14): 1425-1435.
  93. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005. 294(19): 2437-2445.
  94. Underhill H.R., Yuan C., Zhao X.Q., Kraiss L.W., Parker D.L., Saam T., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008. 155(3): 584 e581-588.
  95. Fellstrom B.C., Jardine A.G., Schmieder R.E., Holdaas H., Bannister K., Beutler J., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009. 360(14): 1395-1407.
  96. Avis H.J., Hutten B.A., Gagne C., Langslet G., McCrindle B.W., Wiegman A., et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010. 55(11): 1121-1126.
  97. Giugliano R.P., Mach F., Zavitz K., Kurtz C., Im K., Kanevsky E., et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017. 377(7): 633-643.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

СПИСОК ЛИТЕРАТУРЫ
На предыдущую главу Предыдущая глава
оглавление
Следующая глава